Infrastructure strategy becomes enterprise strategy
How infrastructure capacity, asset lifecycle choices and delivery ecosystems increasingly shape growth, resilience and competitive advantage.
Read articleRelated macro
Chemicals and process industries
Protect competitiveness and unlock portfolio value as feedstock, energy, capacity and regional economics reshape process industries.
Discover the macroEditorial overview
Articles
The new map of strategic dependencies
How raw materials, supply networks and technology competition are redefining where global enterprises remain exposed.
Read articleFocus
Telecom operators still face the problem of turning network investment into growth
AI, network APIs and sovereign digital infrastructure create new opportunities, but connectivity economics remain difficult to escape.
Private capital is becoming more selective as liquidity remains harder to manufacture
Longer holds, constrained exits and tougher fundraising are shifting attention from deployment volume toward realized value and distributions.
Strategic challenges
Who owns the customer when the vehicle becomes a software platform?
The challenge is moving from one-time vehicle economics toward digital services without weakening affordability or product reliability.
How long can private markets grow while liquidity remains structurally constrained?
The challenge is balancing deployment, exits and investor distributions when traditional realization routes remain uneven.
POV
Healthcare cannot hire its way out of every capacity problem
Persistent workforce scarcity makes operating-model redesign a clinical necessity, not merely an efficiency agenda.
Owning the resource does not guarantee control of the supply chain
The strategic chokepoint may sit in refining, processing or trade policy rather than beneath the ground.
Strategic impact
Processing capacity is becoming as strategic as resource ownership
Supply security increasingly depends on smelting, refining and by-product recovery rather than simply securing additional mineral reserves.
New care models can shift scarce clinical capacity toward higher-value work
Virtual care, automation and redesigned pathways can change where patients are treated and which tasks require specialist intervention.
What we observe
Biopharma companies often modernize discovery while leaving development economics unchanged
Faster target identification has limited value if trials, evidence generation and commercialization remain equally slow and expensive.
Telcos often enter adjacent technology markets where specialists hold the economics
Large enterprise deals can add revenue while integration complexity and lower margins dilute the strategic case for becoming a broad tech provider.